You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T-Cell

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Peripheral T Cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing/China, China
  • +1 more
Oct 9, 2023

Peripheral T Cell Lymphoma Trial in Zhengzhou (Golidocitinib, CHOP Regimen)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 18, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (CMOP+Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 1, 2023

T-cell Lymphoma, CLL/SLL Trial in Birmingham (Tazemetostat, Acalabrutinib and Tazemetostat)

Not yet recruiting
  • T-cell Lymphoma
  • CLL/SLL
  • Birmingham, Alabama
    University of Alabama at Birmingham
Aug 11, 2023

Obesity, Fasting, T-Cell Dysfunction Trial (Fasting)

Not yet recruiting
  • Obesity
  • +2 more
  • Fasting
  • (no location specified)
May 23, 2023

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

Active, not recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,

Recruiting
  • Cutaneous T-Cell Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
  • (no location specified)
Mar 7, 2023

T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma Trial in Chicago (Fenretinide)

Not yet recruiting
  • T-cell Lymphoma
  • +10 more
  • Chicago, Illinois
    Rush University Medical Center
Oct 24, 2022

Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma
  • Sugemalimab
  • +4 more
  • (no location specified)
Jan 17, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Peripheral T Cell Lymphoma Trial in Shandong, Shanghai, Sichuan (84-gene penal)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • 84-gene penal
  • Shandong, China
  • +2 more
Jul 6, 2023

Cutaneous T-cell Lymphoma Retreated With Brentuximab Vedotin

Not yet recruiting
  • T-Cell Lymphoma
  • No intervention
  • Bordeaux, France
  • +10 more
May 24, 2023

NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)

Not yet recruiting
  • NK/T Cell Lymphoma
  • +2 more
  • Guangzhou, Guangdong, China
  • +1 more
Jan 12, 2023

Minimal Residual Disease in Peripheral T-cell Lymphoma

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Tumor biopsy
  • +2 more
  • Boston, Massachusetts
  • +2 more
Dec 19, 2022

T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • +4 more
  • anti-CD7 CAR-T cells
  • Shanghai, China
    Xianmin General Song
Aug 29, 2022

Remitoro in Recurrent or Refractory Peripheral T Cell Lymphoma

Recruiting
  • Lymphoma, T-cell, Peripheral
  • Lymphoma, T-cell, Cutaneous
  • Nagoya, Japan
  • +2 more
Nov 24, 2022

Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer Trial in Shanghai (Fludarabine + Cyclophosphamide,

Not yet recruiting
  • Cervical Cancer
  • +6 more
  • Fludarabine + Cyclophosphamide
  • HRYZ-T101 TCR-T Cell
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 27, 2023

Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype Trial in Guangzhou (Chidamide combined with CHOP,

Recruiting
  • Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
  • Guangzhou, Guangdong, China
    Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Oct 7, 2022

T Cell Lymphoma Trial (Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen)

Not yet recruiting
  • T Cell Lymphoma
  • Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen
  • (no location specified)
Mar 6, 2023

Peripheral T Cell Lymphoma Trial in Duarte, Aurora, Philadelphia (Nivolumab and EPOCH)

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Nivolumab and EPOCH
  • Duarte, California
  • +2 more
Jan 6, 2023

Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • (no location specified)
Dec 29, 2022

T Lymphoblastic Leukemia/Lymphoma Trial in Shenzhen (CD7 CAR-T cells)

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • CD7 CAR-T cells
  • Shenzhen, Guangdong, China
    Li Yu
Nov 11, 2022

Peripheral T Cell Lymphoma Trial in Zhengzhou (SHR0302)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 2, 2023